Drug Profile
Research programme: fibrosis therapeutics - Excaliard Pharmaceuticals
Alternative Names: Anti-fibrotic antisense drugs - Excaliard PharmaceuticalsLatest Information Update: 29 Mar 2012
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Excaliard Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Fibrosis; Scars
Most Recent Events
- 29 Mar 2012 No development reported for Fibrosis in USA (unspecified route)
- 29 Mar 2012 No development reported for Scars in USA (unspecified route)
- 02 Dec 2011 Excaliard Pharmaceuticals has been acquired by Pfizer